Evidence map›Paper›PMID 36941438›Full record

ArticleApplied microbiology and biotechnology2023

Sifting through the core-genome to identify putative cross-protective antigens against Riemerella anatipestifer.

Xiangkuan Zheng, Sixiang Xu, Zhuohao Wang, Xingyu Tao, Yuqing Liu, Lei Dai, Yubao Li, Wei Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Applied microbiology and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Applied and environmental microbiology · 2026
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Xiangkuan ZhengThe Sanya Institute of Nanjing Agriculture University, Sanya, 572024, China.
Sixiang XuThe Sanya Institute of Nanjing Agriculture University, Sanya, 572024, China.
Zhuohao WangThe Sanya Institute of Nanjing Agriculture University, Sanya, 572024, China.
Xingyu TaoThe Sanya Institute of Nanjing Agriculture University, Sanya, 572024, China.
Yuqing LiuInstitute of Animal Science and Veterinary Medicine, Shandong Academy of Agricultural Sciences, Jinan, Shandong Province, 250100, China.
Lei DaiHainan Animal Disease Prevention and Control Center, 16 Xingdan Road, Haikou, 571100, China.
Yubao LiAgricultural Science and Engineering School, Liaocheng University, Liaocheng, China. Liyubao@lcu.edu.cn.
Wei ZhangThe Sanya Institute of Nanjing Agriculture University, Sanya, 572024, China. vszw@njau.edu.cn.ORCID http://orcid.org/0000-0002-3575-6225
Nanjing Agricultural University · CNHainan Center for Disease Control & Prevention · CNLiaocheng University · CNShandong Academy of Agricultural Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infectious serositis of ducks, caused by Riemerella anatipestifer, is one of the main infectious diseases that harm commercial ducks. Whole-strain-based vaccines with no or few cross-protection were observed between different serotypes of R. anatipestifer, and so far, control of infection is hampered by a lack of effective vaccines, especially subunit vaccines with cross-protection. Since the concept of reverse vaccinology was introduced, it has been widely used to screen for protective antigens in important pathogens. In this study, pan-genome binding reverse vaccinology, an emerging approach to vaccine candidate screening, was used to screen for cross-protective antigens against R. anatipestifer. Thirty proteins were identified from the core-genome as potential cross-protective antigens. Three of these proteins were recombinantly expressed, and their immunoreactivity with five antisera (anti-serotypes 1, 2, 6, 10, and 11) was demonstrated by Western blotting. Our study established a method for high-throughput screening of cross-protective antigens against R. anatipestifer in silico, which will lay the foundation for the development of a cross-protective subunit vaccine controlling R. anatipestifer infection. KEY POINTS: • Pan-genome binding reverse vaccine approach was first established in R. anatipestifer to screen for subunit vaccine candidates. • Thirty potential cross-protective antigens against R. anatipestifer were identified by this method. • The reliability of the method was verified preliminarily by the results of Western blotting of three of these potential antigens.

Indexed as

Flavobacteriaceae InfectionsPoultry DiseasesRiemerellaAnimalsDucksReproducibility of ResultsVaccines, SubunitVaccines, SubunitCore-genomeCross-protective antigensPan-genomeReverse vaccinologyRiemerella anatipestiferSubunit vaccine

Identifiers

PMID36941438
OpenAlexW4328049166

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.